Editas Medicine Reports $160.1 Million Net Loss for 2025, Revenue Increases to $40.5 Million

Editas Medicine, Inc. reported a net loss of $160.1 million for the year ended December 31, 2025, compared to a net loss of $237.1 million for the previous year. The company's collaboration and other research and development revenues increased to $40.5 million from $32.3 million in 2024, driven by revenue recognition from the BMS collaboration and the Vertex License Agreement. As of December 31, 2025, Editas Medicine held $146.6 million in cash and cash equivalents.

Operating expenses for 2025 totaled $200.5 million, a decrease from $283.5 million in 2024. Research and development expenses significantly decreased to $90.0 million from $199.2 million, primarily due to the discontinuation of the reni-cel program and reduced clinical and manufacturing costs. General and administrative expenses also decreased to $49.9 million from $72.0 million, reflecting reduced employee-related expenses and professional service fees. Restructuring and impairment charges increased to $60.7 million, compared to $12.2 million in the prior year, mainly due to contract termination costs and asset impairments related to the discontinued program.

Key operational developments included the nomination of EDIT-401 as the lead in vivo development candidate, targeting hyperlipidemia, with plans to submit an IND by mid-2026. Preclinical studies of EDIT-401 demonstrated approximately 90% mean reduction of LDL-C in non-human primates. The company also continues to advance its in vivo discovery and development efforts, including research programs targeting hematopoietic stem cells and other tissues. Employee headcount as of February 1, 2026, was 87, with approximately 66 primarily engaged in research and development activities.

Editas Medicine anticipates that its existing cash and cash equivalents will fund operating expenses and capital expenditure requirements into the third quarter of 2027. The company expects to rely on additional financing to achieve its business objectives, which may include equity offerings, debt financings, collaborations, and licensing arrangements. Management believes that the company's current facilities are sufficient to meet its needs and that additional space will be available as needed. The company's common stock continues to trade on the Nasdaq Global Select Market under the symbol "EDIT," but the market price has been and is likely to remain volatile.